Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Hashimoto

Showing results (281-290 of 330) with videos related to

Pageof 33
Sort By:
International Journal of Molecular Sciences|March 1, 2017
An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer DiagnosisTomokazu Ishikawa, Tohru Yoneyama, Yuki Tobisawa, et al.
BJUI Compass|April 27, 2022
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinomaYoshiharu Okuyama, Shingo Hatakeyama, Kazuyuki Numakura, et al.
Oncotarget|June 3, 2017
Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinomaShogo Hosogoe, Shingo Hatakeyama, Ayumu Kusaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 7, 2020
Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective studyToshikazu Tanaka, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Clinical Oncology|October 17, 2020
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective studyKoichi Kido, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 26, 2019
C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinomaSakae Konishi, Shingo Hatakeyama, Toshiaki Tanaka, et al.
Urologic Oncology|January 2, 2022
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective studyDaichi Sasaki, Shingo Hatakeyama, Hideo Kawaguchi, et al.
The EMBO Journal|June 30, 2011
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycansShigeru Tsuboi, Mihoko Sutoh, Shingo Hatakeyama, et al.
Scientific Reports|April 8, 2022
Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipientsTomoko Hamaya, Shingo Hatakeyama, Tohru Yoneyama, et al.
Scientific Reports|June 11, 2022
Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapyHiromichi Iwamura, Shingo Hatakeyama, Takuma Narita, et al.
Pageof 33

Showing results (281-290 of 330) with videos related to

Sort By:
Pageof 33
International Journal of Molecular Sciences|March 1, 2017
An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer DiagnosisTomokazu Ishikawa, Tohru Yoneyama, Yuki Tobisawa, et al.
BJUI Compass|April 27, 2022
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinomaYoshiharu Okuyama, Shingo Hatakeyama, Kazuyuki Numakura, et al.
Oncotarget|June 3, 2017
Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinomaShogo Hosogoe, Shingo Hatakeyama, Ayumu Kusaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 7, 2020
Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective studyToshikazu Tanaka, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Clinical Oncology|October 17, 2020
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective studyKoichi Kido, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 26, 2019
C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinomaSakae Konishi, Shingo Hatakeyama, Toshiaki Tanaka, et al.
Urologic Oncology|January 2, 2022
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective studyDaichi Sasaki, Shingo Hatakeyama, Hideo Kawaguchi, et al.
The EMBO Journal|June 30, 2011
A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycansShigeru Tsuboi, Mihoko Sutoh, Shingo Hatakeyama, et al.
Scientific Reports|April 8, 2022
Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipientsTomoko Hamaya, Shingo Hatakeyama, Tohru Yoneyama, et al.
Scientific Reports|June 11, 2022
Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapyHiromichi Iwamura, Shingo Hatakeyama, Takuma Narita, et al.
Pageof 33